rosuvastatin (CAS 287714-41-4) — formula C22H28FN3O6S, molecular weight 481.5; category organic chemicals.
| CAS Number | 287714-41-4 |
|---|---|
| Molecular Formula | C22H28FN3O6S |
| Molecular Weight | 481.5 |
| LogP | 0.13 |
| Applications | Uses: Hydroxymethylglutaryl-CoA Reductase Inhibitors, MEDICATION, Use (kg, approx.) in Germany (2009): >100, Consumption (g per capita, approx.) in Germany (2009): 0.00122, Calculated removal (%): 24.7, Used as an adjunct to dietary therapy to treat primary hyperlipidemia (heterozygous familial and nonfamilial), mixed dyslipidemia and hypertriglyceridemia. Also indicated for homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering therapies or when other such therapies are not available. Furthermore, it is used to slow the progression of atherosclerosis and for primary prevention of cardiovascular disease., Methods of Manufacturing: The preparation of the intermediate ethyl 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine-5-carboxylate occur according to standard chemical procedures. Reduction to the 5-hydroxymethyl derivative proceeds smoothly with diisobutylaluminum hydride (DIBALH) in toluene at -10 °C. The hydroxymethyl group is then converted to the bromo derivative, which upon reaction with triphenylphosphine affords the Wittig reagent. The latter is treated with tert-butyl 2-[(4R, 6S)-6-formyl-2, 2-dimethyl-1, 3-dioxan-4-yl]acetate and provides the protected rosuvastatin ester. Removal of the dioxane protecting group by HCl, ester hydrolysis with NaOH and precipitation with CaCl2 gives, rosuvastatin, . The 6-formyl side chain intermediate is prepared by oxidation of the corresponding 6-hydroxymethyl compound, e.g., with DMSO-oxalyl chloride., Preparation: K. Hirai et al., European Patent Office patent 521471, eidem, United States of America patent 5260440 (both 1993 to Shionogi)., Formulations, Preparations: Table: Rosuvastatin Preparations [Table#6909] |
| Category | Organic Chemicals |
Documented applications: Uses: Hydroxymethylglutaryl-CoA Reductase Inhibitors, MEDICATION, Use (kg, approx.) in Germany (2009): >100, Consumption (g per capita, approx.) in Germany (2009): 0.00122, Calculated removal (%): 24.7, Used as an adjunct to dietary therapy to treat primary hyperlipidemia (heterozygous familial and nonfamilial), mixed dyslipidemia and hypertriglyceridemia. Also indicated for homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering therapies or when other such therapies are not available. Furthermore, it is used to slow the progression of atherosclerosis and for primary prevention of cardiovascular disease., Methods of Manufacturing: The preparation of the intermediate ethyl 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine-5-carboxylate occur according to standard chemical procedures. Reduction to the 5-hydroxymethyl derivative proceeds smoothly with diisobutylaluminum hydride (DIBALH) in toluene at -10 °C. The hydroxymethyl group is then converted to the bromo derivative, which upon reaction with triphenylphosphine affords the Wittig reagent. The latter is treated with tert-butyl 2-[(4R, 6S)-6-formyl-2, 2-dimethyl-1, 3-dioxan-4-yl]acetate and provides the protected rosuvastatin ester. Removal of the dioxane protecting group by HCl, ester hydrolysis with NaOH and precipitation with CaCl2 gives, rosuvastatin, . The 6-formyl side chain intermediate is prepared by oxidation of the corresponding 6-hydroxymethyl compound, e.g., with DMSO-oxalyl chloride., Preparation: K. Hirai et al., European Patent Office patent 521471, eidem, United States of America patent 5260440 (both 1993 to Shionogi)., Formulations, Preparations: Table: Rosuvastatin Preparations [Table#6909].
rosuvastatin is a carbon-based organic compound with CAS registry number 287714-41-4 and molecular formula C22H28FN3O6S (molecular weight 481.5), belonging to the organic chemicals segment of chemical raw materials.
CAS number: 287714-41-4
Its molecular formula C22H28FN3O6S comprises 22 C, 28 H, 1 F, 3 N, 6 O, 1 S atoms.
Also known as: rosuvastatin · 瑞舒伐他汀
Category: organic chemicals
The CAS registry number of rosuvastatin is 287714-41-4.
Molecular formula C22H28FN3O6S, molecular weight 481.5.
It is also registered under: rosuvastatin, 瑞舒伐他汀.
Recorded applications: Uses: Hydroxymethylglutaryl-CoA Reductase Inhibitors, MEDICATION, Use (kg, approx.) in Germany (2009): >100, Consumption (g per capita, approx.) in Germany (2009): 0.00122, Calculated removal (%): 24.7, Used as an adjunct to dietary therapy to treat primary hyperlipidemia (heterozygous familial and nonfamilial), mixed dyslipidemia and hypertriglyceridemia. Also indicated for homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering therapies or when other such therapies are not available. Furthermore, it is used to slow the progression of atherosclerosis and for primary prevention of cardiovascular disease., Methods of Manufacturing: The preparation of the intermediate ethyl 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine-5-carboxylate occur according to standard chemical procedures. Reduction to the 5-hydroxymethyl derivative proceeds smoothly with diisobutylaluminum hydride (DIBALH) in toluene at -10 °C. The hydroxymethyl group is then converted to the bromo derivative, which upon reaction with triphenylphosphine affords the Wittig reagent. The latter is treated with tert-butyl 2-[(4R, 6S)-6-formyl-2, 2-dimethyl-1, 3-dioxan-4-yl]acetate and provides the protected rosuvastatin ester. Removal of the dioxane protecting group by HCl, ester hydrolysis with NaOH and precipitation with CaCl2 gives, rosuvastatin, . The 6-formyl side chain intermediate is prepared by oxidation of the corresponding 6-hydroxymethyl compound, e.g., with DMSO-oxalyl chloride., Preparation: K. Hirai et al., European Patent Office patent 521471, eidem, United States of America patent 5260440 (both 1993 to Shionogi)., Formulations, Preparations: Table: Rosuvastatin Preparations [Table#6909].
Category: Organic Chemicals.
Independent reference data for rosuvastatin (CAS 287714-41-4), compiled from public chemistry databases.
| CAS Registry Number | 287714-41-4 |
|---|---|
| PubChem CID | 446157 |
| Molecular formula | C22H28FN3O6S |
| IUPAC name | (E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid |
| UNII (FDA) | 413KH5ZJ73 |
| Molecular Weight | 481.5 |
|---|---|
| XLogP3 | 1.6 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 10 |
| Exact Mass | 481.16828496 |
| Monoisotopic Mass | 481.16828496 |
| Topological Polar Surface Area | 149 |
| Heavy Atom Count | 33 |
| Solubility | 8.86e-02 g/L |
|---|---|
| LogP | 0.13 |
| LogP | 2.4 |
| Ionization Efficiency | 2.53 |
| Ionization Efficiency | 2.7 |
| Ionization Efficiency | MeCN (80%) |
Rosuvastatin; 287714-41-4; Creston; X-Plended; ZD4522; Rosuvastatina; ZD-4522; 413KH5ZJ73; DTXSID8048492; CHEBI:38545; rosuvastatinum; RefChem:6205; C10AA07; DTXCID90820057; rosuvastatine; Rosuvastatin [INN]
| Reported hazard statements | H351 (90%), H360 (90%), H411 (10%), H412 (90%) |
|---|
H351 (90%): Suspected of causing cancer [Warning Carcinogenicity]
H360 (90%): May damage fertility or the unborn child [Danger Reproductive toxicity]
rosuvastatin · CAS 287714-41-4 · C22H28FN3O6S. UNII 413KH5ZJ73. Solubility: 8.86e-02 g/L; LogP: 0.13; LogP: 2.4.
Source: PubChem / Wikidata; the batch COA governs where values differ.
Supplier: Jinan Shenghe Chemical Co., Ltd.
中文页面: 瑞舒伐他汀